Prostate cancer is the most common cancer in men across Nigeria and Ghana. GLOBOCAN 2022 data — the authoritative global cancer database published by the International Agency for Research on Cancer under the WHO — records prostate cancer as accounting for approximately 29% of all new male cancer cases in Nigeria and a similarly dominant share in Ghana. Despite this burden, most men in West Africa are diagnosed at advanced stages because PSA screening is not routinely available and awareness of early prostate cancer symptoms remains limited.
India offers a practical, affordable, and medically excellent pathway for Nigerian and Ghanaian prostate cancer patients — from early-stage robotic surgery to advanced castration-resistant disease management. This guide covers every treatment option, what it costs, what the outcomes look like, and how to start the process from West Africa.
| 💬 Free Prostate Cancer Evaluation — WhatsApp: +91 9205491370 |
Prostate Cancer in Nigeria and Ghana — Why Late Diagnosis Is Common
Two structural factors drive late-stage prostate cancer diagnosis across West Africa. First, routine PSA (prostate-specific antigen) screening — the blood test that detects prostate cancer before symptoms develop — is not part of standard healthcare practice in Nigeria or Ghana for most men. In high-income countries, PSA testing for men above 50 is standard, leading to early-stage diagnoses where cure rates exceed 95%. In Nigeria and Ghana, most diagnoses occur when the patient presents with symptoms: urinary difficulty, bone pain from metastases, or weight loss.
Second, men in West Africa — consistent with global patterns — are often reluctant to discuss urological symptoms or attend health screenings. The result is a disease that is biologically similar to prostate cancer anywhere in the world but is encountered at a much more advanced stage, limiting curative options.
The important message for Nigerian and Ghanaian men reading this: if you are over 45, have never had a PSA test, and have a family history of prostate cancer — a PSA test at any laboratory is the single most valuable thing you can do today. Early detection saves lives.
Understanding Your Diagnosis — PSA, Gleason Score, and Stage
PSA Level — What the Numbers Mean
- PSA below 4 ng/mL: generally normal (though aggressive cancers can occur with low PSA)
- PSA 4–10 ng/mL: borderline — biopsy often recommended
- PSA above 10 ng/mL: elevated — biopsy strongly recommended
- PSA above 100 ng/mL: typically indicates metastatic disease
Gleason Score — Understanding Your Biopsy Result
The Gleason score grades prostate cancer aggressiveness from 6 (least aggressive) to 10 (most aggressive) based on the biopsy specimen. Gleason 6 = low risk, suitable for active surveillance or local treatment. Gleason 7 (3+4 or 4+3) = intermediate risk — usually treated. Gleason 8–10 = high risk — systemic therapy often combined with local treatment.
Prostate Cancer Treatment Options in India — By Stage
Early-Stage (Localised) Prostate Cancer — Stage T1–T2
For localised prostate cancer (cancer confined to the prostate gland), India offers two main curative treatment options — radical prostatectomy and radiation therapy — with outcomes comparable to the world’s leading cancer centres.
Robotic-Assisted Radical Prostatectomy (RARP)
Da Vinci robotic-assisted laparoscopic prostatectomy is available at BLK-Max, Fortis Memorial, and Apollo Hospitals in Delhi. The robotic approach offers superior precision compared to open surgery, with the key advantages being:
- Significantly less blood loss and lower transfusion requirement
- Faster recovery — most patients discharged within 3–4 days
- Better preservation of urinary continence and erectile function (nerve-sparing technique)
- Cancer control outcomes equivalent to open surgery for appropriately staged disease
- Cost in India: $4,500 – $7,000 (compared to $15,000–$25,000 in South Africa private and $30,000–$50,000 in USA)
Radiation Therapy — IMRT and Stereotactic Body Radiation (SBRT)
For patients who prefer radiation over surgery, or who have co-morbidities making surgery high-risk, India’s cancer centres offer:
- IMRT (Intensity-Modulated Radiation Therapy): precisely shaped radiation beams targeting the prostate. 7–8 week treatment course. Cost: $4,000–$7,000.
- SBRT (Stereotactic Body Radiation / CyberKnife): high-dose, highly targeted radiation in 4–5 sessions. Equivalent outcomes to IMRT with shorter treatment course. Available at Fortis Memorial and BLK-Max. Cost: $5,000–$8,000.
- Brachytherapy: radioactive seeds implanted directly in the prostate. Used for low-risk disease. Cost: $5,000–$7,000.
Intermediate and High-Risk Localised Prostate Cancer
For Gleason 7–10 disease or Stage T3 (cancer beginning to extend beyond the prostate), the standard approach in India follows international guidelines: radical prostatectomy (with lymph node dissection) or radiation therapy combined with androgen deprivation therapy (ADT — hormone therapy to suppress testosterone, which fuels prostate cancer growth). Duration of ADT: 6 months for intermediate risk, 2–3 years for high risk.
Metastatic Prostate Cancer — Options in India
For patients with bone or lymph node metastases at diagnosis—the most common scenario for late-presenting Nigerian and Ghanaian patients—curative treatment is not possible, but India offers highly effective life-prolonging therapies:
- Androgen Deprivation Therapy (ADT): Leuprolide or degarelix injections + bicalutamide. Cost in India significantly lower than Africa private pharmacies.
- Docetaxel chemotherapy: for high-volume metastatic disease upfront. Available at all major Indian cancer centres. Cost: $800–$1,500 per cycle.
- Novel hormonal agents: Enzalutamide and Abiraterone — game-changing drugs for castration-resistant prostate cancer. Available as generics in India at dramatically reduced cost compared to branded versions.
- PSMA-targeted radionuclide therapy (Lutetium-177 PSMA): available at selected centres including Tata Memorial for PSMA-positive castration-resistant disease.
Prostate Cancer Treatment Cost in India for Nigerian and Ghanaian Patients
| Treatment | India Cost | South Africa Private | UK Private | Locally Available in Nigeria/Ghana |
| Robotic Prostatectomy (RARP) | $4,500–$7,000 | $15,000–$25,000 | $30,000–$50,000 | Very limited |
| IMRT Radiation (full course) | $4,000–$7,000 | $12,000–$20,000 | $25,000–$40,000 | Very limited |
| SBRT / CyberKnife (5 sessions) | $5,000–$8,000 | $15,000–$25,000 | $30,000+ | Not available |
| ADT (Leuprolide injection/3 months) | $150–$300 | $800–$1,500 | $1,000–$2,000 | Available, costly |
| Docetaxel chemo (per cycle) | $800–$1,500 | $3,000–$6,000 | $5,000–$10,000 | Available, costly |
| Enzalutamide (month supply — generic) | $300–$600 | $3,000–$5,000 | $4,000–$6,000 | Very limited |
| PSMA PET scan (staging) | $400–$600 | $1,500–$3,000 | $2,000+ | Not available |
How to Start: Sending Your Reports to MediKaya Healthcare
Getting a prostate cancer evaluation from an Indian oncologist does not require traveling to India first. The entire initial assessment can be done remotely in 48 hours via WhatsApp:
- Gather your available medical records: PSA test result (with date), prostate biopsy pathology report (showing Gleason score), any imaging (CT scan, bone scan, or MRI of the pelvis), and any previous treatment records.
- Send these to MediKaya via WhatsApp: +91 9205491370. Include your age, current symptoms, and any treatment already received.
- MediKaya’s oncology partner reviews your case within 48 hours. Written recommendation: stage assessment, treatment options, specific hospital recommendation, cost estimate.
- If you wish to proceed: medical visa arranged (3–5 days), hospital booking confirmed, coordinator assigned.
- Arrive in Delhi. Treatment begins within 3–5 days of arrival.
Frequently Asked Questions — Prostate Cancer India Nigeria Ghana
Q: My PSA is 28 and the biopsy shows Gleason 3+4. I am 62 years old. What is my treatment option in India?
A: Gleason 3+4 (Grade Group 2) with PSA 28 places this in the intermediate-to-high-risk localised category. The staging question — whether cancer has spread beyond the prostate — depends on MRI pelvis and PSMA PET scan, which MediKaya would arrange on arrival. If localised, both robotic prostatectomy and IMRT+ADT are curative options with equivalent long-term cancer control. At 62 with PSA 28, most centres in India would offer radical prostatectomy with nerve-sparing if MRI shows organ-confined disease. MediKaya’s urological oncologist will review your biopsy and any imaging you have.
Q: I am from Lagos and my father has been diagnosed with prostate cancer that has spread to his bones. Is it too late for treatment in India?
A: Metastatic prostate cancer with bone involvement is not curable, but it is very treatable — and the modern treatments available in India can significantly extend both length and quality of life. ADT combined with newer agents like Enzalutamide or Abiraterone has dramatically improved outcomes for metastatic prostate cancer. A PSMA PET scan (available in India for $400–$600) would map the extent of disease and guide treatment planning. Please send us your father’s recent PSA level, biopsy report, and any bone scan or CT results.
Q: How long will my husband need to stay in India for robotic prostatectomy?
A: Robotic prostatectomy typically requires 10–14 days in India total. This includes 2–3 days of pre-operative assessment, the surgery itself (3–4 hours), 3–4 days hospital stay post-surgery, and 3–5 days observation before travel clearance. PSA is checked at 4–6 weeks post-surgery — this can be done at any laboratory in Nigeria or Ghana, with the result sent to MediKaya’s oncologist via WhatsApp.
Q: Is generic Enzalutamide from India as effective as the branded version?
A: Generic Enzalutamide (branded: Xtandi) manufactured by Indian companies (including Cipla and Sun Pharma) contains the same active pharmaceutical ingredient, produced under CDSCO regulatory approval. Bioequivalence requirements ensure the same pharmacokinetic profile as the originator. Indian-manufactured Enzalutamide is widely used internationally including in WHO-approved programmes. Cost in India: $300–$600 per month vs $4,000–$6,000 for branded Xtandi in the UK.